Novotech kicks off Phase Ib trials in Australia and NZ for OncoMed
Wednesday, 03 November, 2010
California-based biopharma company, OncoMed Pharmaceuticals, has announced it will run three Phase Ib clinical trials in Australia and New Zealand testing its humanised monoclonal antibody therapies for cancer.
The three separate trials, which have begun enrollment, are targeting patients pancreatic cancer, advanced colorectal cancer, and non-squamous non-small cell lung cancer (NSCLC).
OncoMed's treatments use monoclonal antibodies to target specific biologic pathways that are critical to tumour initiating cells, or so-called 'cancer stem cells'.
The trials will be run in Australia and New Zealand through the Sydney-based contract research organisation, Novotech.
Novel antibiotic activates 'suicide' mechanism in superbug
Researchers have discovered a new class of antibiotic that selectively targets Neisseria...
Modifications in the placenta linked to psychiatric disorders
Schizophrenia, bipolar disorder and major depression disorder are the neuropsychiatric disorders...
ADHD may be linked with an increased risk of dementia
An adult brain affected by attention deficit hyperactivity disorder (ADHD) presents modifications...
